KRAS and non-small cell lung carcinoma: The first, sotorasib, is a KRAS G12C inhibitor that significantly increased PFS and had a more favorable safety profile than docetaxel in patients with advanced NSCLC harboring the KRASm G12C mutation who had previously been treated with other anticancer drugs (20).